THERAPY DOSSIER · th-3f6d3f020445

miR-155 antagomir

Other

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Wound
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 25264197 ↗2014Reported benefit

Acute downregulation of miR-155 at wound sites leads to a reduced fibrosis through attenuating inflammatory response.

MouseWoundC57BL/6MaleLocal injection into the wound edge

Model: Cutaneous wound with subsequent skin fibrosis

Local miR-155 antagomir injection reduced immune cell recruitment, lowered IL-1beta and TNF-alpha and raised IL-10, and reduced alpha-SMA, Col1 and Col3 at both mRNA and protein level. Collagen fibres were more regularly arranged, indicating reduced fibrosis, while the rate of wound healing did not…

Extraction: extract · Supplied extraction confidence: 0.65. Machine-extracted fields require source verification.

Loading the evidence…